Morpine is developed by China Medical University Hospital.

What development phase is Morpine in?

Morpine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Morpine

China Medical University Hospital · FDA-approved active Small molecule Quality 0/100

Morpine, marketed by China Medical University Hospital, holds a position in the pharmaceutical market with its key composition patent set to expire in 2028. The drug's primary strength lies in its current market presence, leveraging the established reputation of China Medical University Hospital. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	Morpine
Sponsor	China Medical University Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

NALDEBAIN for Postoperative Pain Management in Take Down of Anastomosis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Morpine CI brief — competitive landscape report
Morpine updates RSS · CI watch RSS
China Medical University Hospital portfolio CI